COVID-19

India’s Omicron cases mild, vaccine boosters not a priority – government

Reuters
India’s Omicron cases mild, vaccine boosters not a priority – government

FILE PHOTO: A woman receives Bharat Biotech's coronavirus disease (COVID-19) vaccine called COVAXIN at a vaccination centre as her husband takes her picture, in New Delhi, India, on April 5, 2021.

Adnan Abidi/Reuters

Sources say India has not considered authorizing boosters yet as many in the country have been naturally infected and the government believes two vaccine doses offer sufficient protection for now

NEW DELHI, India – India has detected 25 cases of the emergent Omicron variant of the coronavirus and all have shown mild symptoms, the health ministry said on Friday, December 10, adding that there was no immediate plan to authorize vaccine boosters.

Vaccine supplies have surged in India in recent months thanks to the Serum Institute of India (SII), which now plans to halve the monthly output of its version of the AstraZeneca vaccine as demand has crashed.

The SII and other Indian drugmakers such as Dr. Reddy’s Laboratories, which distributes Russia’s Sputnik vaccine, have lobbied the government to approve booster shots in a bid to lift sales.

Senior health official Vinod Kumar Paul told a news briefing that government experts were studying data on boosters but “our emphatic view…is to [first] cover every adult with [just] the primary two doses.”

The government has said this target can be achieved by January.

India has not considered authorizing booster doses yet as many in the country have been naturally infected and the government believes two vaccine doses offer sufficient protection for now, three informed sources told Reuters late last month.

Around 87% of India’s adults, estimated at 939 million people, have received at least one dose of a vaccine and 54% of them have received the full two. Inoculations for those under the age of 18 years have not started.

Paul spoke after the World Health Organization recommended that people with compromised immunity or those who received an inactivated vaccine should receive a booster.

Inactivated vaccines, which use killed or inactivated coronavirus to induce immunity, is made by India’s Bharat Biotech and some Chinese companies.

At 144 million doses, Bharat Biotech’s Covaxin accounts for about 11% of the total vaccine doses administered in India. Many Indian healthcare workers received Covaxin early this year and some experts say they should soon be allowed to take a booster.

India’s daily new COVID-19 cases have hovered around 10,000 for the past few weeks, taking the total to 34.67 million, more than 474,000 of whom have died.

Most contracted the Delta variant, though Omicron has spread to five states after India’s first two cases were reported on December 2. “All detected cases have mild symptoms,” a health ministry statement said. – Rappler.com